Canertinib

Drug Profile

Canertinib

Alternative Names: Canertinib dihydrochloride; CI-1033; PD 0183805; PD 183805

Latest Information Update: 03 Sep 2015

Price : $50

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Morpholines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Head and neck cancer; Ovarian cancer
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 10 Sep 2007 Data presented at the 12th World Conference on Lung Cancer (WCLC-2007) added to the adverse events and Cancer therapeutic trials sections
  • 18 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the adverse events, pharmacokinetics and Cancer therapeutic trials sections
  • 07 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the adverse events and Cancer therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top